Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetic patients with insulin resistance
Journal of Diabetes Investigation Dec 01, 2017
Hattori S - The physicians aimed to investigate the effect of empagliflozin (EMPA) on remnant-like particle cholesterol (RLP-C) in type 2 diabetic patients with insulin resistance. RLP-C levels were decreased with EMPA, which was closely related to amelioration of insulin sensitivity in diabetic patients who presented with insulin resistance.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
